Learning Objectives:

1. Translational models of primary and secondary drug resistance in invasive thyroid cancer.

2. Role of stem cell-like pericytes in resistance to BRAFV600E inhibitors and tyrosine kinase inhibitors (TKI).

3. Role of a newly-identified thyroid-specific lincRNA in thyroid cancer.

Session date: 
Monday, February 15, 2021 - 5:00pm to 6:00pm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Carmelo Nucera, M.D., Ph.D.